Published in Cancer Weekly, September 9th, 2003
According to a study from the United States, "Some degree of peripheral edema occurs in up to 20% of patients treated with gemcitabine (Gemzar). The edema is typically mild, requiring discontinuation of the drug in less than 1% of patients. Most patients require no therapy."
"However, in cases of peripheral edema grade II or higher, suspension of gemcitabine and treatment with corticosteroids are often necessary, and permanent discontinuation of gemcitabine may be required on occasion," wrote C.G. Azzoli and colleagues, Memorial Sloan Kettering Cancer Center.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly